Bicara presents survival data for ficerafusp alfa + Keytruda in head/neck cancer: 21.3 months median OS, 46% 2-year OS rate ...

Checkpoint therapies like Keytruda, Opdivo, and Imfinzi are expanding from late-stage to early-stage cancer treatment, with ...

Takeda and Protagonist Therapeutics are on the comeback trail with rusfertide, almost four years after the rare blood disease ...

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

AstraZeneca and Handa Pharmaceuticals have agreed to pay a combined $51.4 million to resolve a class action lawsuit that ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...